Browsing Category
Pharma Industry News
4728 posts
Business-News-Today.com section for global pharma industry news, Indian pharma sector latest news, pharma sector news today, pharmaceuticals industry news.
EMA moves Protalix (PLX) closer to extended dosing approval for Elfabrio in Fabry disease
Protalix BioTherapeutics secures EMA panel backing for monthly Elfabrio dosing in Fabry disease, unlocking a $25M milestone. See what it means for PLX.
Castanospermine commercialization strategy evolves as Sixty Degrees Pharmaceuticals pursues non prescription market entry
Discover why Sixty Degrees Pharmaceuticals is shifting castanospermine toward non prescription market entry and what this means for execution, risk, and investor strategy.
Incyte breaks new ground in EU cancer care with first PD‑1 drug for tough gastrointestinal tumors
Discover how Incyte’s EU backing for its MacroGenics‑partnered cancer drug Zynyz could shift immunotherapy competition in gastrointestinal cancers.
Why did Amgen Inc. walk away from its $1.25bn eczema drug deal with Kyowa Kirin?
Amgen Inc. exits its $1.25B eczema drug deal with Kyowa Kirin Co., Ltd., reshaping its immunology focus. Find out what this move means for both companies’ pipelines.
EYLEA HD and DUPIXENT anchor Regeneron’s 2026 growth plan amid clinical pipeline acceleration
Find out how Regeneron’s 18 new Phase III trials and four FDA approval targets in 2026 aim to reshape growth beyond DUPIXENT and EYLEA. Read the full story.
Can Galmed Pharmaceuticals avoid delisting? Nasdaq compliance clock is ticking
Nasdaq has notified Galmed Pharmaceuticals of a share price deficiency. Find out what this means for investors and the company's future strategy.
What’s going on at Olema Oncology? CFO + COO Hans Bishop exits suddenly
Olema Oncology CFO and COO Hans Bishop has stepped down ahead of OP-1250 trial milestones. Find out what this means for investors and pipeline strategy.
Astec LifeSciences (ASTEC) reports narrowed Q3 loss as CDMO momentum drives positive EBITDA
Astec LifeSciences posts â‚ą125.5 crore in Q3 FY26 revenue with positive EBITDA. Find out how CDMO gains and margin recovery are reshaping the outlook today.
How the Nautilus Biotechnology and Michael J. Fox Foundation alliance signals a shift in Parkinson’s biomarker strategy (NASDAQ: NAUT)
Find out how Nautilus Biotechnology’s Parkinson’s collaboration signals a strategic shift in biomarker platforms and what it means for investors and drug developers.
Zervimesine development highlights regulatory complexity in dementia with Lewy bodies
Zervimesine moves closer to Phase 2b as Cognition Therapeutics engages FDA. Read how regulatory complexity is shaping dementia drug development.